Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Investment Perspective

Scancell’s outlook has been transformed by the recent investment by Redmile of a further £12.1m in equity and £17.9m in Convertible Loan Notes (CLN). These funds, together with an over-subscribed £3m Open Offer, boost Scancell’s cash to c £48m. After a sustained period of being under-resourced, attention now turns to execution and delivery. The additional funds will be used to progress and broaden the ImmunoBody and Moditope portfolios and further develop the Avidimab platform. The onus will inevitably shift to timely progress across a broader front, including clinical data for SCIB1, Modi-1, and COVIDITY and, in time, material commercial partnerships for Avidimab. With a change in management and in line with our policy, we suspend our forecasts and valuation with the intention of reinstating these pending an update on any changes to strategic priorities and/or timelines.

Market information

SymbolPrimary exchanges


CTA approval confirms H221 COVIDITY Phase I start
Lighthouse | 30 Jul 2021
COVIDITY programme to start Phase I in H221
Lighthouse | 22 Jun 2021
H121 results highlight shift to delivery and execution
Lighthouse | 29 Jan 2021

Recent News

First patient dosed in SCIB1 Phase II trial
19 Nov 2021
Results for the year ended 30 April 2021
29 Oct 2021
First subject dosed in South Africa Phase I COVIDITY trial
05 Oct 2021
Modi-1 Phase I/II clinical trial application approved by MHRA
26 Aug 2021